Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Moderna (NASDAQ:MRNA) Inc on Monday, setting a price target of $95, which is approximately 29.76% above the present share price of $73.21.
Livshits expects Moderna Inc to post earnings per share (EPS) of -$0.35 for the third quarter of 2020.
The current consensus among 17 TipRanks analysts is for a Strong Buy rating of shares in Moderna, with an average price target of $91.87.
The analysts price targets range from a high of $134 to a low of $65.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $8.39 million and a net profit of -$130.86 million. The company's market cap is $27.18 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 38.3% and a 73.56% success rate.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.